Abbott Laboratories (ABT.N)
ABT.N on New York Stock Exchange
70.76USD
14 Dec 2018
70.76USD
14 Dec 2018
Change (% chg)
$-1.42 (-1.97%)
$-1.42 (-1.97%)
Prev Close
$72.18
$72.18
Open
$71.17
$71.17
Day's High
$71.48
$71.48
Day's Low
$70.38
$70.38
Volume
1,872,345
1,872,345
Avg. Vol
1,721,856
1,721,856
52-wk High
$74.91
$74.91
52-wk Low
$54.63
$54.63
Consensus Recommendations
| Consensus Recommendation | Next Earnings (approx.) | Company Fiscal Year End Month |
Last Updated |
|---|---|---|---|
| Outperform | 0.81 | December | 17 Dec 2018 |
Analyst Recommendations and Revisions
| 1-5 Linear Scale | Current | 1 Month Ago |
2 Month Ago |
3 Month Ago |
|---|---|---|---|---|
| (1) BUY | 9 | 8 | 8 | 8 |
| (2) OUTPERFORM | 8 | 7 | 6 | 6 |
| (3) HOLD | 3 | 4 | 4 | 4 |
| (4) UNDERPERFORM | 0 | 0 | 0 | 0 |
| (5) SELL | 0 | 0 | 0 | 0 |
| No Opinion | 0 | 0 | 0 | 0 |
| Mean Rating | 1.70 | 1.79 | 1.78 | 1.78 |
Consensus Estimates Analysis
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| # of Estimates | Mean | High | Low | 1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Dec-18 | 18 | 7,824.56 | 7,920.00 | 7,703.03 | 7,813.31 |
| Quarter Ending Mar-19 | 11 | 7,655.17 | 7,868.10 | 7,471.33 | 7,451.03 |
| Year Ending Dec-18 | 20 | 30,657.60 | 31,041.00 | 30,516.00 | 30,163.10 |
| Year Ending Dec-19 | 20 | 32,214.20 | 33,225.00 | 31,669.50 | 31,989.80 |
| Earnings (per share) | |||||
| Quarter Ending Dec-18 | 20 | 0.81 | 0.82 | 0.80 | 0.80 |
| Quarter Ending Mar-19 | 14 | 0.66 | 0.75 | 0.63 | 0.64 |
| Year Ending Dec-18 | 22 | 2.88 | 2.90 | 2.86 | 2.83 |
| Year Ending Dec-19 | 22 | 3.20 | 3.26 | 3.11 | 3.19 |
| LT Growth Rate (%) | 6 | 11.47 | 13.00 | 7.10 | 11.49 |
Historical Surprises
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Estimates vs Actual | Estimate | Actual | Difference | Surprise % |
|---|---|---|---|---|
| SALES (in millions) | ||||
| Quarter Ending Sep-18 | 7,650.64 | 7,656.00 | 5.36 | 0.07 |
| Quarter Ending Jun-18 | 7,711.53 | 7,767.00 | 55.47 | 0.72 |
| Quarter Ending Mar-18 | 7,285.94 | 7,390.00 | 104.06 | 1.43 |
| Quarter Ending Dec-17 | 7,385.90 | 7,589.00 | 203.10 | 2.75 |
| Quarter Ending Sep-17 | 6,716.81 | 6,829.00 | 112.19 | 1.67 |
| Earnings (per share) | ||||
| Quarter Ending Sep-18 | 0.75 | 0.75 | 0.00 | 0.58 |
| Quarter Ending Jun-18 | 0.71 | 0.73 | 0.02 | 2.86 |
| Quarter Ending Mar-18 | 0.58 | 0.59 | 0.01 | 1.71 |
| Quarter Ending Dec-17 | 0.73 | 0.74 | 0.01 | 1.07 |
| Quarter Ending Sep-17 | 0.65 | 0.66 | 0.01 | 1.18 |
Consensus Estimates Trend
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Current | 1 Week Ago |
1 Month Ago |
2 Month Ago |
1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Dec-18 | 7,824.56 | 7,824.56 | 7,822.51 | 7,949.68 | 7,813.31 |
| Quarter Ending Mar-19 | 7,655.17 | 7,655.17 | 7,650.26 | 7,669.44 | 7,451.03 |
| Year Ending Dec-18 | 30,657.60 | 30,657.60 | 30,656.80 | 30,754.60 | 30,163.10 |
| Year Ending Dec-19 | 32,214.20 | 32,214.20 | 32,238.40 | 32,491.10 | 31,989.80 |
| Earnings (per share) | |||||
| Quarter Ending Dec-18 | 0.81 | 0.81 | 0.81 | 0.82 | 0.80 |
| Quarter Ending Mar-19 | 0.66 | 0.66 | 0.66 | 0.67 | 0.64 |
| Year Ending Dec-18 | 2.88 | 2.88 | 2.89 | 2.89 | 2.83 |
| Year Ending Dec-19 | 3.20 | 3.20 | 3.20 | 3.24 | 3.19 |
Estimates Revisions Summary
| Last Week | Last 4 Weeks | |||
|---|---|---|---|---|
| Number Of Revisions: | Up | Down | Up | Down |
| Revenue | ||||
| Quarter Ending Dec-18 | 0 | 0 | 0 | 1 |
| Quarter Ending Mar-19 | 0 | 0 | 0 | 1 |
| Year Ending Dec-18 | 0 | 0 | 0 | 1 |
| Year Ending Dec-19 | 0 | 0 | 0 | 2 |
| Earnings | ||||
| Quarter Ending Dec-18 | 0 | 0 | 0 | 1 |
| Quarter Ending Mar-19 | 0 | 0 | 0 | 2 |
| Year Ending Dec-18 | 0 | 0 | 0 | 2 |
| Year Ending Dec-19 | 0 | 0 | 0 | 3 |
Earnings vs. 
Estimates- CORRECTED-FOCUS-U.S. regulators snip red tape for medical devices to curb opioid crisis
- FOCUS-U.S. regulators snip red tape for medical devices to curb opioid crisis
- UPDATE 2-Abbott, AbbVie settle TriCor marketing case for $25 mln
- Abbott, AbbVie settle U.S. case over TriCor marketing for $25 mln
- AbbVie CFO Chase to retire by mid-year 2019